Context Therapeutics reports preclinical CTIM-76 data showing tumor regressions; IND on track for Q1 2024

Context Therapeutics Inc.

CTIM-76 induced dose-proportional tumor regressions and was well tolerated in xenograft models.
CTIM-76 showed ten-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation assays.
CTIM-76 retained activity across low to high CLDN6 expression, unlike TORL-1-23 which depended on high expression.
IND filing for CTIM-76 planned for late Q1 2024.
Approximately 70,000 US patients with CLDN6-positive metastatic solid tumors have no approved targeted treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.